Cardiac Surgery Devices Market Size, Share, Growth Analysis 2032
Cardiac Surgery Devices Market Size and Forecast (2025 - 2032), By Product Type (Perfusion Devices, Catheters, Beating Heart Surgery Systems, Heart Lung Machines, Cardiac Ablation Devices, Others), By Application (Congenital Heart Defects, Cardiac Arrhythmia, Coronary Artery Disease, Heart Valve Disease, Others), By End User (Hospitals, Speciality Clinics, Ambulatory Surgery Centres, Others), and Geography.
Market Overview:
The Cardiac Surgery Devices Market is expected to reach a high CAGR of 3.1% over the Forecast Period 2025-2032., with the market value rising from USD XX in 2024 to USD YY by 2032. North America now dominates the market, accounting for the vast majority of worldwide sales. Key metrics include rising cardiovascular disease prevalence, technological breakthroughs in cardiac surgery instruments, and increased demand for minimally invasive procedures.
The market is expanding rapidly due to an ageing population, an increase in the prevalence of heart illness, and ongoing advancements in cardiac surgery procedures. Emerging economies are giving enormous development potential as healthcare infrastructure improves and healthcare expenditure increases.
Market Dynamics:
Market Trend: Minimally invasive procedures gain traction, revolutionising cardiac surgeries and patient outcomes.
The cardiac surgical equipment market is undergoing a considerable change towards less invasive techniques. The multiple benefits of these procedures, including fewer incisions, less stress, faster recovery times, and a lower chance of problems, are driving this trend. Minimally invasive cardiac surgeries (MICS) are gaining popularity for a variety of procedures, including valve repair and replacement, coronary artery bypass grafting (CABG), and atrial fibrillation treatment. The use of robotic-assisted surgical devices has expedited this trend, allowing surgeons to conduct difficult surgeries with more precision and control. The demand for MICS-specific devices, such as specialised catheters, endoscopes, and suturing devices, is increasing.
Furthermore, advances in imaging technologies, such as 3D visualisation systems and augmented reality, are facilitating the expansion of minimally invasive cardiac procedures. As more patients and healthcare professionals recognise the benefits of these treatments, the market for MICS-specific devices is likely to grow dramatically in the coming years.
Market Driver: The ageing population and rising prevalence of cardiovascular diseases fuel market growth.
The global ageing population and increased prevalence of cardiovascular illnesses are important drivers of the cardiac surgery devices market. According to the World Health Organisation, cardiovascular disease is the leading cause of death worldwide, killing an estimated 17.9 million people each year. The chance of acquiring heart-related illnesses grows with age, and with the global population of 65 and older predicted to reach 1.5 billion by 2050, demand for cardiac procedures is expected to skyrocket.
According to the Centres for Disease Control and Prevention, heart disease kills approximately 655,000 Americans each year, accounting for one out of every four deaths. This high prevalence results in an increasing need for cardiac surgical interventions, as well as an increased need for improved cardiac surgery technology. Furthermore, lifestyle factors such as sedentary behaviours, bad diets, and high stress levels are contributing to the rising incidence of heart disease across all age groups, which is driving market growth.
Market Restraint: High costs associated with cardiac surgery devices limit market penetration.
The high cost of cardiac surgery devices limits market expansion, particularly in developing and underdeveloped nations. Advanced cardiac surgery devices, such as heart-lung machines, robot-assisted surgical systems, and specialised imaging equipment, are often expensive.
For example, a cutting-edge robotic surgical system can cost upwards of $2 million, plus additional per-procedure charges. These significant initial investments and continuous operational costs might strain hospital budgets and limit the use of modern cardiac surgery instruments in many facilities. Furthermore, the cost of cardiac surgeries utilising these modern technologies is frequently passed on to patients, rendering such procedures unaffordable for a sizable section of the population in nations without adequate healthcare coverage. This pricing barrier not only reduces market penetration but also leads to healthcare inequities, preventing many patients from receiving sophisticated cardiac surgery therapies.
Segment Overview:
Perfusion devices dominate the cardiac surgery devices market, driven by their critical role in maintaining patient circulation during procedures.
Perfusion devices, such as heart-lung machines and oxygenators, are critical in cardiac surgeries because they keep blood circulation and oxygen levels stable during procedures that need the heart to be temporarily stopped. These gadgets have undergone major technological developments in recent years, resulting in increased efficiency, safety, and convenience of use. This segment's dominance is based on the importance of these devices in a wide range of cardiac procedures, from coronary artery bypass grafting to heart valve replacements.
The global market for perfusion devices in cardiac surgery was worth around $YY billion in 2023, with forecasts predicting consistent expansion in the next few years. This expansion is being driven by an increase in the number of cardiac procedures performed worldwide, as well as continual advances in perfusion technology. For example, the development of miniaturised perfusion systems has allowed for their use in less invasive operations, broadening their applications.
Recent industry advances have strengthened the position of perfusion devices in the cardiac surgery device market. In late 2023, a top medical device manufacturer developed a next-generation heart-lung machine with expanded monitoring capabilities and a better user interface, therefore improving the safety and efficiency of cardiovascular procedures. Collaborations between perfusion device manufacturers and artificial intelligence companies are also opening the path for smarter, more automated perfusion systems, which promise to improve patient outcomes while reducing perfusionist workloads during complex cardiac procedures.
Regional Outlook:
North America leads the cardiac surgery devices market, driven by advanced healthcare infrastructure and a high prevalence of cardiovascular diseases.
North America's dominance in the cardiac surgery devices market is due to a number of reasons, including the region's advanced healthcare infrastructure, high healthcare expenditure, and the presence of major cardiac device manufacturers. The United States, in particular, accounts for a sizable portion of the global market due to its huge patient population and early adoption of breakthrough medical technologies.
The high frequency of cardiovascular disorders strengthens the region's leadership. According to the American Heart Association, approximately half of all individuals in the United States have some kind of cardiovascular illness, resulting in a high need for cardiac surgical procedures. Because of the high illness load and favourable reimbursement rules for cardiac treatments, the cardiac surgical devices industry has grown steadily.
The FDA recently approved a revolutionary transcatheter aortic valve replacement (TAVR) system, which will extend treatment options for patients with severe aortic stenosis in early 2024. This approval is expected to improve the North American market for cardiac surgery devices, especially in the minimally invasive category.
In 2023, North America accounted for almost YY% of the global cardiac surgery device revenue. In the same year, the United States performed over 500,000 cardiac surgeries, the majority of which were CABG and valve replacement procedures.
Canada has also made important contributions to the region's market growth, with its publicly supported healthcare system ensuring widespread access to cardiac surgery treatments. The Canadian government's recent pledge of a $500 million investment in cardiovascular health research and treatment is projected to fuel market growth in the years ahead.
Competitive Intelligence:
The cardiac surgery equipment market is characterised by fierce competition between established medical device companies and emerging startups. Market giants like Medtronic, Abbott Laboratories and Boston Scientific Corporation maintain their dominant positions by utilising their vast product portfolios, global presence, and major R&D investments. These organisations have prioritised strategic acquisitions and collaborations to broaden their product offerings and geographic reach.
As of 2023, the top five companies accounted for nearly YY% of the worldwide cardiac surgery devices market. Medtronic led with approximately YY% of the market, followed closely by Abbott Laboratories at YY%. Boston Scientific and Edwards Lifesciences both had approximately 10-12% of the market.
The competitive landscape has recently shifted towards a greater emphasis on minimally invasive and transcatheter technology. For example, Edwards Lifesciences has witnessed tremendous growth in its transcatheter aortic valve replacement (TAVR) market, with sales expected to increase by 15% year on year in 2023. Similarly, Boston Scientific has grown its structural heart portfolio through internal development and strategic acquisitions.
In the future, advances in artificial intelligence and robotics in cardiac surgery will undoubtedly impact the competitive landscape. Several businesses are making significant investments in developing AI-powered surgical planning tools and robotic-assisted surgical systems. Furthermore, there is a growing emphasis on developing devices that interact with digital health systems, allowing for remote patient monitoring and data-driven decision-making in cardiovascular care.
Analyst Opinion:
The market for cardiac surgery equipment is expected to grow and shift significantly in the future years. The intersection of technological breakthroughs, shifting patient demographics, and evolving healthcare delivery models is providing fertile ground for innovation in this field. One unique development to watch is the incorporation of artificial intelligence and machine learning algorithms into cardiac surgery devices. These technologies have the potential to significantly improve surgical planning, intraoperative decision-making, and postoperative care.
Another significant change is the shift towards value-based healthcare models, which is anticipated to boost demand for technologies that not only enhance surgical outcomes but also exhibit long-term cost-effectiveness. This tendency may favour the use of minimally invasive and transcatheter devices that can shorten hospital stays and lower complication rates.
Furthermore, the increased emphasis on personalised treatment is projected to drive the development of patient-specific cardiac devices, thus opening up new opportunities for 3D printing in cardiac surgery. As these trends play out, organisations that can successfully negotiate the regulatory landscape while providing creative, cost-effective solutions are likely to emerge as market leaders.
Major Players:
-
Medtronic plc
-
Abbott Laboratories
-
Boston Scientific Corporation
-
Edwards Lifesciences Corporation
-
LivaNova PLC
-
Terumo Corporation
-
Getinge AB
-
AtriCure, Inc.
-
Koninklijke Philips N.V.
-
Stryker Corporation
Key Developments:
-
In January 2024, Medtronic got FDA approval for its next-generation transcatheter aortic valve implantation (TAVI) device, which features a revised valve design for better patient outcomes.
-
Abbott Laboratories and a top AI business formed a strategic agreement in March 2024 to create AI-powered diagnostic solutions for cardiac imaging.
1. INTRODUCTION
1.1. Market Definitions & Study Assumptions
1.2. Market Research Scope and Segment
1.3. Research Methodology
2. EXECUTIVE SUMMARY
2.1. Market Overview & Insights
2.2. Segment Outlook
2.3. Region Outlook
3. COMPETITIVE INTELLIGENCE
3.1. Companies Financial Position
3.2. Company Benchmarking—Key Players
3.3. Market Share Analysis -- Key Companies
3.4. Recent Companies Key Activities
3.5. Pricing Analysis
3.6. SWOT Analysis
4. COMPANY PROFILES (Key Companies List by Country) (Premium)
5. COMPANY PROFILES
5.1. Medtronic plc
5.2. Abbott Laboratories
5.3. Boston Scientific Corporation
5.4. Edwards Lifesciences Corporation
5.5. LivaNova PLC
5.6. Terumo Corporation
5.7. Getinge AB
5.8. AtriCure, Inc.
5.9. Koninklijke Philips N.V.
5.10. Stryker Corporation (LIST NOT EXHAUSTIVE)
6. MARKET DYNAMICS
6.1. Market Trends
6.1.1. Minimally invasive procedures gain traction, revolutionising cardiac surgeries
6.1.2. Integration of artificial intelligence in cardiac surgery devices
6.1.3. Rise of personalised medicine in cardiac care
6.2. Market Drivers
6.2.1. Ageing population and rising prevalence of cardiovascular diseases
6.2.2. Technological advancements in cardiac surgery devices
6.2.3. Increasing healthcare expenditure in emerging economies
6.3. Market Restraints
6.3.1. High costs associated with cardiac surgery devices
6.3.2. Stringent regulatory approval processes
6.4. Market Opportunities
6.5. Porter's Five Forces Analysis
6.5.1. Threat of New Entrants
6.5.2. Bargaining Power of Buyers/Consumers
6.5.3. Bargaining Power of Suppliers
6.5.4. Threat of Substitute Products
6.5.5. Intensity of Competitive Rivalry
6.6. Supply Chain Analysis
6.7. Value Chain Analysis
6.8. Trade Analysis
6.9. Pricing Analysis
6.10. Regulatory Analysis
6.11. Patent Analysis
6.12. SWOT Analysis
6.13. PESTLE Analysis
7. BY PRODUCT TYPE (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2025-2032)
7.1. Perfusion Devices
7.1.1. Heart-lung Machines
7.1.2. Oxygenators
7.1.3. Perfusion Tubing Sets
7.2. Catheters
7.2.1. Angiography Catheters
7.2.2. Guiding Catheters
7.2.3. Pulmonary Artery Catheters
7.3. Beating Heart Surgery Systems
7.4. Heart Lung Machines
7.5. Cardiac Ablation Devices
7.5.1. Radiofrequency Ablators
7.5.2. Cryoablation Devices
7.5.3. Microwave Ablators
7.6. Others
8. BY APPLICATION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH)--2025-2032)
8.1. Congenital heart defects
8.1.1. Atrial Septal Defect
8.1.2. Ventricular Septal Defect
8.1.3. Others
8.2. Cardiac Arrhythmia
8.2.1. Atrial Fibrillation
8.2.2. Ventricular Tachycardia
8.2.3. Others
8.3. Coronary Artery Disease
8.4. Heart Valve Disease
8.4.1. Aortic Valve Disease
8.4.2. Mitral Valve Disease
8.4.3. Others
8.5. Others
9. BY END USER (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2025-2032)
9.1. Hospitals
9.2. Speciality Clinics
9.3. Ambulatory Surgery Centres
9.4. Others
10. REGION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2025-2032)
10.1. North America
10.1.1. United States
10.1.2. Canada
10.1.3. Mexico
10.2. South America
10.2.1. Brazil
10.2.2. Argentina
10.2.3. Rest of South America
10.3. Europe
10.3.1. Germany
10.3.2. United Kingdom
10.3.3. France
10.3.4. Italy
10.3.5. Spain
10.3.6. Russia
10.3.7. Rest of Europe
10.4. Asia-Pacific
10.4.1. China
10.4.2. Japan
10.4.3. India
10.4.4. Australia
10.4.5. South Korea
10.4.6. Rest of Asia-Pacific
10.5. Middle-East
10.5.1. UAE
10.5.2. Saudi Arabia
10.5.3. Turkey
10.5.4. Rest of Middle East
10.6. Africa
10.6.1. South Africa
10.6.2. Egypt
10.6.3. Rest of Africa
*NOTE: All the regions mentioned in the scope will be provided with (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (2025-2032)
By Product Type:
-
Perfusion Devices
-
Catheters
-
Beating Heart Surgery Systems
-
Heart-lung machines
-
Cardiac Ablation Devices
-
Others
By Application:
-
Congenital heart defects
-
Cardiac Arrhythmia
-
Coronary Artery Disease
-
Heart Valve Disease
-
Others
By End User:
-
Hospitals
-
Speciality Clinics
-
Ambulatory Surgery Centres
-
Others
By Region:
-
North America
-
Europe
-
Asia-Pacific
-
Latin America
-
Middle East & Africa
Frequently Asked Questions
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511